Lyudmila A. Bazhenova, MD

Articles

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15th 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15th 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

The Potential Role of TKIs in HER2-Mutated NSCLC

May 8th 2024

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC

May 8th 2024

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

April 24th 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Role of ADCs in HER2-Mutated NSCLC

April 24th 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Biomarker Testing Challenges in HER2-mutated NSCLC

April 17th 2024

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

Diagnosing HER2-mutated NSCLC

April 17th 2024

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC

January 18th 2024

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC

December 1st 2023

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care

October 26th 2023

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.

Dr Bazhenova on Identifying Gaps in EGFR-Mutated Lung Cancer Care

October 13th 2023

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of collaborative efforts when approaching gaps in lung cancer care.

Dr Bazhenova on Treating Patients With Advanced NSCLC Harboring EGFR Mutations

September 6th 2023

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

July 29th 2023

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

August 16th 2022

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Dr. Bazhenova on Larotrectinib and Entrectinib in NTRK Fusion–Positive NSCLC

July 30th 2022

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Dr. Bazhenova on Questions With Trastuzumab Deruxtecan in HER2-Mutated Lung Cancer

February 9th 2022

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.